Tesamorelin: Turning Up the Body's Own Growth-Hormone Rhythm

The short version

Tesamorelin is a synthetic version of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone (GH). It is FDA-approved for one specific population: adults with HIV who have developed lipodystrophy — abnormal, excess accumulation of visceral (deep abdominal) fat as a side effect of antiretroviral therapy. It is given as a once-daily subcutaneous injection.

The clearest, most consistently repeated finding across tesamorelin's trial record is a reduction in visceral adipose tissue. A 2026 meta-analysis pooling five randomized controlled trials found significant reductions in visceral fat, trunk fat, and liver fat, alongside a gain in lean body mass, without serious adverse events ^[6]. Earlier individual trials found comparable effects going back to 2008 ^[8][9][10].

This page describes what tesamorelin was studied for, in whom, and what the evidence shows — not a recommendation for any individual, and not a dose to follow outside its approved, prescribed use.

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone — GHRH(1-44)-NH2 — with a trans-3-hexenoic acid group attached to its N-terminus. That modification is the whole trick: it makes the molecule resistant to cleavage by the enzyme dipeptidyl peptidase-IV (DPP-IV), which would otherwise break down native GHRH within minutes, extending tesamorelin's plasma stability enough to make it usable as a once-daily therapy. Its empirical formula, as the free base, is C221H366N72O67S; it is supplied clinically as the acetate salt.

Because it stimulates the body's own GHRH receptor rather than supplying growth hormone directly, tesamorelin preserves the pulsatile pattern of natural GH release — GH secreted in bursts rather than as a flat, continuous level — which researchers consider mechanistically distinct from giving recombinant GH itself.

How it works

Tesamorelin binds the growth-hormone-releasing hormone receptor (GHRH-R) on somatotroph cells in the anterior pituitary, activating a Gs-protein/adenylyl-cyclase/cAMP/PKA signaling cascade that stimulates synthesis and pulsatile secretion of endogenous growth hormone. That GH then drives the liver to produce insulin-like growth factor-1 (IGF-1); GH and IGF-1 together promote lipolysis — the breakdown of stored fat — with a documented preference for visceral fat over other fat depots.

Because the mechanism runs through the body's own regulatory axis rather than delivering GH directly, a 2011 study in 13 healthy men found that two weeks of tesamorelin significantly raised overnight GH and IGF-1 levels while leaving fasting glucose and insulin-stimulated glucose uptake unaffected ^[9] — a reassuring signal, since exogenous GH itself is well known to worsen insulin sensitivity at high doses.

What the research shows

2026 meta-analysis (five RCTs). Pooling five randomized controlled trials in HIV-associated lipodystrophy, tesamorelin significantly reduced visceral adipose tissue (mean difference -27.71 cm², 95% CI -38.37 to -17.06; P<0.001), trunk fat (-1.18 kg), and hepatic fat fraction (-4.28%), while increasing lean body mass (+1.42 kg) — all statistically significant, without serious adverse events across the pooled trials ^[6].

Regulatory history and liver-safety monograph. Tesamorelin was approved in the United States in 2010 specifically to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy. The NIH's LiverTox monograph assigns it a likelihood score of 'E' — an unlikely cause of clinically apparent liver injury — noting no reported cases of attributable liver injury and no new serum-enzyme elevations across its trials ^[7].

JAMA randomized trial (2014). In a 6-month trial of 50 antiretroviral-treated adults with HIV (28 on tesamorelin, 22 on placebo), tesamorelin 2 mg/day produced a treatment effect of -42 cm² in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) ^[8].

Mechanistic trial in healthy men (2011). In 13 healthy men without HIV, two weeks of tesamorelin 2 mg/day increased mean overnight GH by 0.5 µg/L (P=0.004) and raised IGF-1 by 181 µg/L (P<0.0001), while neither fasting glucose (P=0.93) nor insulin-stimulated glucose uptake (P=0.61) changed significantly ^[9].

52-week program data (2008). Across a full year of treatment (2 mg/day, n=273, versus placebo n=137), visceral-fat reduction was sustained at -18% relative to baseline (P<0.001); visceral fat re-accumulated after participants stopped the drug, and glucose-parameter changes over the full year were not clinically significant ^[10].

Reported effects, cautions & safety

As with MOTS-c, Chai Peptides has not assembled a structured set of community-reported-effects data for tesamorelin — its use is concentrated in a specific clinical population working with prescribing physicians rather than in the broad research-community discussion that surrounds a compound like tirzepatide, and this desk does not invent that texture where it does not exist in the sourced record.

What the cited literature does establish is a set of real, if narrow, clinical cautions. Tesamorelin's FDA approval is limited strictly to HIV-associated lipodystrophy; every other proposed use — general visceral-fat reduction, anti-aging applications, cognitive support — is off-label and has not been established by large randomized trials in those populations. The visceral-fat benefit is not durable on its own: trial data show visceral fat re-accumulates within weeks of stopping the drug, meaning any benefit depends on continued use ^[10]. Because the mechanism raises IGF-1, a growth factor, active malignancy is a labeled contraindication, and while trials have not shown an excess cancer signal over roughly a year of use, long-term oncologic safety data remain limited. Modest glucose perturbation can occur, warranting monitoring in people with prediabetes, though the dedicated study in healthy men found no significant change in insulin sensitivity ^[9]. Cognitive findings are mixed across the literature — encouraging in some aging populations, not significantly different from standard care in a 2025 HIV-cognition trial. Tesamorelin is also a GHRH analogue and is prohibited in sport under the WADA Prohibited List (category S2), in- and out-of-competition.

Where it fits in appetite, satiety, and metabolic-signaling research

Tesamorelin occupies the hormone-axis layer on this desk — its mechanism runs through the pituitary and liver rather than through gut-hormone receptors like tirzepatide or the direct cellular energy-sensing pathway proposed for MOTS-c. Where the other two compounds are studied primarily for appetite and whole-body weight, tesamorelin's best-established effect is narrower and more specific: reallocating fat away from the visceral depot in a defined clinical population, with lean-mass preservation as a secondary benefit. It is also the most tightly regulated of the three — an approved drug for one indication, rather than an investigational research chemical or a broadly approved weight-management therapy. See the comparison page for how all three line up.